Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as oxaliplatin and docetaxel, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. It is not yet known whether
vandetanib is more effective than a placebo when given together with oxaliplatin and
docetaxel in treating advanced cancer of the esophagus or gastroesophageal junction.
PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
vandetanib when given together with oxaliplatin and docetaxel and to see how well it works in
treating patients with advanced cancer of the esophagus or gastroesophageal junction.